Please login to the form below

Not currently logged in
Email:
Password:

Hybrigenics appoints Dr Alain Munoz

France-based bio-pharmaceutical company Hybrigenics has appointed Dr Alain Munoz to its board of directors

France-based bio-pharmaceutical company Hybrigenics has appointed Dr Alain Munoz to its board of directors.

Dr Munoz replaces Dr Bernhard Ehmer, president of ImClone Systems, and will chair the clinical advisory board.

He has over 20 years' experience in the pharmaceutical industry at senior management level with the Sanofi Group as R&D vice-president and the French pharmaceutical company Fournier as VP of R&D and business development, subsequently becoming senior VP of the pharmaceutical division.

As well as his position at Hybrigenics, Dr Munoz is also a board member of several biotechnology companies including Novagali Pharma and Zealand Pharma.

5th October 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...
Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....

Infographics